[HTML][HTML] COVID-19 and bone loss: a review of risk factors, mechanisms, and future directions
A Creecy, OD Awosanya, A Harris, X Qiao… - Current Osteoporosis …, 2024 - Springer
Abstract Purpose of Review SARS-CoV-2 drove the catastrophic global phenomenon of the
COVID-19 pandemic resulting in a multitude of systemic health issues, including bone loss …
COVID-19 pandemic resulting in a multitude of systemic health issues, including bone loss …
[HTML][HTML] Physical activity in patients with neuromuscular disease three years after COVID-19, a longitudinal survey: the after-effects of the quarantine and the benefits …
I Leale, V Giustino, P Trapani, P Alonge, N Rini… - Journal of Clinical …, 2024 - mdpi.com
Background: Quarantine was one of the strategies adopted by governments against the
spread of COVID-19. This restriction has caused an increase in sedentary behaviors and a …
spread of COVID-19. This restriction has caused an increase in sedentary behaviors and a …
[HTML][HTML] Prognostic indicators for hospitalization and ICU admission in people with multiple sclerosis and COVID-19: an analysis of the COVID-19 in MS global data …
MA Garcia-Dominguez, V Kipkorir… - Annals of Medicine and …, 2024 - journals.lww.com
Objectives: To analyze the symptoms and severity of coronavirus disease 2019 (COVID-19)
in people with multiple sclerosis (pwMS) on disease-modifying therapies using data from the …
in people with multiple sclerosis (pwMS) on disease-modifying therapies using data from the …
[HTML][HTML] The impact of COVID-19 infection, the pandemic and its associated control measures on patients with Pompe disease
MTM Theunissen, RM van den Elsen, TL House… - Journal of …, 2024 - Springer
Abstract Background Patients with Pompe disease, a rare metabolic myopathy, were thought
to be at increased risk of severe COVID-19 disease during the pandemic. In addition, the …
to be at increased risk of severe COVID-19 disease during the pandemic. In addition, the …
[HTML][HTML] Identification of key genes as potential diagnostic and therapeutic targets for comorbidity of myasthenia gravis and COVID-19
L Huang, Y Zuo, H Yang, X He, L Zhang - Frontiers in Neurology, 2024 - frontiersin.org
Introduction Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder.
Coronavirus disease 2019 (COVID-19) has a significant impact on the health and quality of …
Coronavirus disease 2019 (COVID-19) has a significant impact on the health and quality of …
Evaluation of SARS-CoV-2 Vaccine-Induced Antibody Responses in Patients with Neuroimmunological Disorders: A Real-World Experience
This study evaluates the antibody responses to SARS-CoV-2 vaccines in patients with
neuroimmunological disorders (pwNID) who are receiving immunomodulating treatments …
neuroimmunological disorders (pwNID) who are receiving immunomodulating treatments …
Impact of COVID-19 pandemic on the incidence and severity of myasthenia gravis in Korea: using National Health Insurance Service database
S Kim, EK Lee, H Kim, H Kim, E Sohn - Frontiers in Neurology, 2024 - frontiersin.org
Background This study investigated the impact of COVID-19 pandemic on the incidence and
severity of myasthenia gravis (MG) using the National Health Insurance Service (NHIS) …
severity of myasthenia gravis (MG) using the National Health Insurance Service (NHIS) …
The PNS Nurse Program: A Health Care Support Concept for Patients With Immune-Mediated Peripheral Nervous System Diseases
M Pawlitzki, M Gasis, L Masanneck… - Neurology: Clinical …, 2024 - AAN Enterprises
Background Immune-mediated peripheral nervous system (PNS) disorders pose diagnostic
and therapeutic challenges, necessitating collaborative, patient-centered care. Limited …
and therapeutic challenges, necessitating collaborative, patient-centered care. Limited …
Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes
ZM Kefalopoulou, D Veltsista, A Germeni… - Neurological …, 2024 - Springer
Background Rituximab, a B-cell depleting monoclonal antibody, represents an option for the
treatment of refractory myasthenia gravis (MG). Its use is more established in muscle-specific …
treatment of refractory myasthenia gravis (MG). Its use is more established in muscle-specific …
The challenges faced by patients with hereditary myopathy during the COVID-19 pandemic
Background: Neuromuscular diseases are inherited and the prevalance of neuromuscular
disease is estimated to be around 1: 2000. Methods: This cross-sectional research was …
disease is estimated to be around 1: 2000. Methods: This cross-sectional research was …